Skip to main content
Erschienen in: Diabetologia 10/2004

01.10.2004 | Article

N-acetyl-cysteine accelerates transfer of diabetes into non-obese diabetic scid mice

verfasst von: J. Irie, A. Shimada, Y. Oikawa, T. Shigihara, T. Saruta

Erschienen in: Diabetologia | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Type 1 diabetes mellitus is caused by autoimmune pancreatic beta cell destruction, and the destructive process involves several molecular mechanisms including oxygen-reactive species. A cysteine derivative, N-acetyl-cysteine, is widely used as an antioxidant, but the role of N-acetyl-cysteine in the protection of pancreatic beta cells in Type 1 diabetes remains unclear. The aim of this study was to clarify the effect of N-acetyl-cysteine on beta cells using an adoptive transfer system in a murine model of Type 1 diabetes.

Methods

Splenocytes from diabetic female non-obese diabetic mice were transferred into female non-obese diabetic scid/scid recipients to induce diabetes. Just after transfer, N-acetyl-cysteine was administered to non-obese diabetic scid recipients. Two weeks after transfer, the pancreas of the recipients was examined histologically, and cytokine mRNA expression in the pancreas was analysed. In vitro, CD4-positive splenocytes from diabetic donor mice were stimulated with anti-CD3 and anti-CD28 antibodies with or without N-acetyl-cysteine.

Results

Treatment with N-acetyl-cysteine significantly accelerated the transfer of diabetes into non-obese diabetic scid recipients. Treatment with N-acetyl-cysteine accelerated the infiltration of mononuclear cells accompanied by CD8-positive cells into the intra-islet region of the recipient’s pancreas, and enhanced interferon-gamma mRNA expression in the pancreas. In vitro, treatment with N-acetyl-cysteine enhanced interferon-gamma and interleukin-2 production by CD4-positive splenocytes of the diabetic donor mice.

Conclusions/interpretation

N-acetyl-cysteine accelerates the transfer of diabetes into non-obese diabetic scid mice and this effect is accompanied by the promotion of local infiltration and T-helper cell type 1 responses.
Literatur
1.
Zurück zum Zitat Mathis D, Vence L, Benoist C (2001) β-cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed Mathis D, Vence L, Benoist C (2001) β-cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed
2.
Zurück zum Zitat Nomikos IN, Wang Y, Lafferty KJ (1989) Involvement of O2 radicals in “autoimmune” diabetes. Immunol Cell Biol 67:85–87PubMed Nomikos IN, Wang Y, Lafferty KJ (1989) Involvement of O2 radicals in “autoimmune” diabetes. Immunol Cell Biol 67:85–87PubMed
3.
Zurück zum Zitat Corbett JA, Mikhael A, Shimizu J et al. (1993) Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 90:8992–8995PubMed Corbett JA, Mikhael A, Shimizu J et al. (1993) Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 90:8992–8995PubMed
4.
Zurück zum Zitat Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T (1995) Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem Biophys Res Commun 209:953–958CrossRefPubMed Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T (1995) Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem Biophys Res Commun 209:953–958CrossRefPubMed
5.
Zurück zum Zitat Piganelli JD, Flores SC, Cruz C et al. (2002) A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51:347–355PubMed Piganelli JD, Flores SC, Cruz C et al. (2002) A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51:347–355PubMed
6.
Zurück zum Zitat Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155–194CrossRefPubMed Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155–194CrossRefPubMed
7.
Zurück zum Zitat Tepel M, Giet M van der, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184CrossRefPubMed Tepel M, Giet M van der, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184CrossRefPubMed
8.
Zurück zum Zitat Tepel M, Giet M van der, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 107:992–995CrossRefPubMed Tepel M, Giet M van der, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 107:992–995CrossRefPubMed
9.
Zurück zum Zitat Eylar E, Rivera-Quinones C, Molina C, Baez I, Molina F, Mercado CM (1993) N-acetylcysteine enhances T cell functions and T cell growth in culture. Int Immunol 5:97–101PubMed Eylar E, Rivera-Quinones C, Molina C, Baez I, Molina F, Mercado CM (1993) N-acetylcysteine enhances T cell functions and T cell growth in culture. Int Immunol 5:97–101PubMed
10.
Zurück zum Zitat Puerto M, Guayerbas N, Victor VM, Fuente MD (2002) Effects of N-acetylcysteine on macrophage and lymphocyte functions in a mouse model of premature ageing. Pharmacol Biochem Behav 73:797–804CrossRefPubMed Puerto M, Guayerbas N, Victor VM, Fuente MD (2002) Effects of N-acetylcysteine on macrophage and lymphocyte functions in a mouse model of premature ageing. Pharmacol Biochem Behav 73:797–804CrossRefPubMed
11.
Zurück zum Zitat Murata Y, Amao M, Hamuro J (2003) Sequential conversion of the redox status of macrophages dictates the pathological progression of autoimmune diabetes. Eur J Immunol 33:1001–1011CrossRefPubMed Murata Y, Amao M, Hamuro J (2003) Sequential conversion of the redox status of macrophages dictates the pathological progression of autoimmune diabetes. Eur J Immunol 33:1001–1011CrossRefPubMed
12.
Zurück zum Zitat Oikawa Y, Shimada A, Kasuga A et al. (2003) Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 171:5865–5875PubMed Oikawa Y, Shimada A, Kasuga A et al. (2003) Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 171:5865–5875PubMed
13.
Zurück zum Zitat Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305–312CrossRefPubMed Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305–312CrossRefPubMed
14.
Zurück zum Zitat Kaneto H, Kajimoto Y, Miyagawa J et al. (1999) Beneficial effects of antioxidants in diabetes. Diabetes 48:2398–2406PubMed Kaneto H, Kajimoto Y, Miyagawa J et al. (1999) Beneficial effects of antioxidants in diabetes. Diabetes 48:2398–2406PubMed
15.
Zurück zum Zitat Tarbell KV, Lee M, Ranheim E et al. (2002) CD4+ T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. J Exp Med 196:481–492CrossRefPubMed Tarbell KV, Lee M, Ranheim E et al. (2002) CD4+ T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. J Exp Med 196:481–492CrossRefPubMed
16.
Zurück zum Zitat Yim CY, Hibbs JB, McGregor JR, Galinsky RE, Samlowski WE (1994) Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol 152:5796–5805PubMed Yim CY, Hibbs JB, McGregor JR, Galinsky RE, Samlowski WE (1994) Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol 152:5796–5805PubMed
17.
Zurück zum Zitat Boon ACM, Vos AP, Graus YMF, Rimmelzwaan GF, Osterhaus ADME (2002) In vitro effect of bioactive compounds on influenza virus specific B- and T-cell responses. Scand J Immunol 55:24–32CrossRefPubMed Boon ACM, Vos AP, Graus YMF, Rimmelzwaan GF, Osterhaus ADME (2002) In vitro effect of bioactive compounds on influenza virus specific B- and T-cell responses. Scand J Immunol 55:24–32CrossRefPubMed
18.
Zurück zum Zitat Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 95:3071–3076CrossRefPubMed Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 95:3071–3076CrossRefPubMed
19.
Zurück zum Zitat Monick MM, Samavati L, Butler NS et al. (2003) Intracellular thiols contribute to Th2 function via a positive role in IL-4 production. J Immunol 171:5107–5115PubMed Monick MM, Samavati L, Butler NS et al. (2003) Intracellular thiols contribute to Th2 function via a positive role in IL-4 production. J Immunol 171:5107–5115PubMed
20.
Zurück zum Zitat Shimada A, Charlton B, Edwards CT, Fathman CG (1996) β-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45:1063–1067PubMed Shimada A, Charlton B, Edwards CT, Fathman CG (1996) β-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45:1063–1067PubMed
21.
Zurück zum Zitat Berman MA, Sandborg CI, Wang Z et al. (1996) Decreased IL-4 production in new onset type 1 insulin-dependent diabetes mellitus. J Immunol 157:4690–4696PubMed Berman MA, Sandborg CI, Wang Z et al. (1996) Decreased IL-4 production in new onset type 1 insulin-dependent diabetes mellitus. J Immunol 157:4690–4696PubMed
22.
Zurück zum Zitat Delovitch TL, Singh B (1997) The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727–738CrossRefPubMed Delovitch TL, Singh B (1997) The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727–738CrossRefPubMed
Metadaten
Titel
N-acetyl-cysteine accelerates transfer of diabetes into non-obese diabetic scid mice
verfasst von
J. Irie
A. Shimada
Y. Oikawa
T. Shigihara
T. Saruta
Publikationsdatum
01.10.2004
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 10/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1529-x

Weitere Artikel der Ausgabe 10/2004

Diabetologia 10/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.